Enterprise "Evolution"
Release time:
2020-08-14
Enterprise "Evolution"
It is said that in ancient times, there were no giraffes on the African savannah. With the change of ecological environment, there is less food in the lower places. Deers try their best to stretch their necks to eat the leaves in the higher places. Those with longer necks are more likely to eat the tender leaves in the higher places of the forest, and it is easier to find out the enemy's situation in advance and avoid harm. As a result, over time, the deer with longer necks are easier to survive and the deer with short necks are disappearing.
This "said" is a bit like a joke, which does not necessarily conform to the real reproduction history of giraffe, an endemic species in Africa, but the truth contained in it is very consistent with Darwin's "survival of the fittest" view in "Evolution. In fact, not only the giraffe, but also the existence of all species in the world must have their own inherent advantages; the disappearance of species that cannot adapt to the external environment must be one of the main factors. natural selection, survival of the fittest, this is the only criterion of biological evolution.
The principle of the biological world is very simple and cruel, so is it true for enterprises in the market competition? The replacement of industry, the reshuffle of industry, the birth and disappearance of enterprises are very similar to the natural elimination of the biological world. In today's era, in the special ecological environment of the market, "natural disasters" and "man-made impacts" are far more complex and severe than the biological world. If enterprises want to find opportunities in these ups and downs, they can only comply with the needs of the times and the market and take the development path of "survival of the fittest.
Some people may say that many enterprises are constantly adjusting and changing, but they still fail to withstand the impact of the market. How can this be explained? In fact, biological evolution has provided us with a good example. The dinosaur family that once ruled the earth for thousands of years also evolved from single-celled animals. When the climate changed dramatically, they quickly died out because they could not adapt to the environment and became fossils in museums. After that, a group of weak monkeys came to the ground from the trees, from climbing on all fours to walking upright, from using ready-made stones and sticks to consciously making tools, and finally from the food of beasts to the primate of all things. Of course, not all companies that disappear in the market reject "evolution", but the direction of "evolution", the speed of "evolution", and the way of "evolution" all directly affect the final "evolution" results. In other words, "evolution" is the basic need for the survival and development of life, but whether the goal of "survival and development" can be achieved must pass the final test of "survival of the fittest.
The final existence of species is not completely determined by their position in the biological chain, the size of the population, and the strength of their strength. In the corporate world, there is no shortage of examples of small but always popular monopolies falling apart. Of course, there are many reasons for this result, but the most important point must be the fit between their own "evolution" and the times and the market. The market is in turn, and only those companies that continue to seek change and self-"evolution", and finally establish incomparable advantages of their peers, and become the "fittest" in the times and market environment. Whether it is a company or a team, if it is rejected by the external environment, how can it talk about "changing the world" and "creating the era"?
Organism realizes the reproduction of species through continuous evolution, and enterprises realize long-term survival and development through continuous "evolution". In the small "ecosystem" of enterprises, as the "molecules" of enterprises, what choices should each employee make? (Hong Tao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page